Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.
IPO Date: April 20, 2012
Sector: Healthcare
Industry: Biotech
Market Cap: $171.75M
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.25 | 3.12%
Avg Daily Range (30 D): $0.06 | 1.77%
Avg Daily Range (90 D): $0.08 | 2.45%
Institutional Daily Volume
Avg Daily Volume: .6M
Avg Daily Volume (30 D): .26M
Avg Daily Volume (90 D): .29M
Trade Size
Avg Trade Size (Sh.): 118
Avg Trade Size (Sh.) (30 D): 100
Avg Trade Size (Sh.) (90 D): 101
Institutional Trades
Total Inst.Trades: 3,680
Avg Inst. Trade: $2.05M
Avg Inst. Trade (30 D): $.89M
Avg Inst. Trade (90 D): $1.52M
Avg Inst. Trade Volume: .05M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $2.59M
Avg Closing Trade (30 D): $.89M
Avg Closing Trade (90 D): $.74M
Avg Closing Volume: 77.08K
   
News
Apr 30, 2025 @ 10:00 AM
Er-Kim Announces Exclusive Distribution Agreement ...
Source: N/A
Jul 18, 2024 @ 11:58 PM
Puma Biotechnology executive sells over $9,600 in ...
Source: Investing.Com
Jul 3, 2024 @ 1:45 AM
Puma biotech exec sells shares worth over $19,000 ...
Source: Investing.Com
Jul 3, 2024 @ 1:45 AM
Puma Biotechnology executive sells over $14,000 in...
Source: Investing.Com
Jul 3, 2024 @ 1:45 AM
Puma Biotechnology CFO sells shares worth over $17...
Source: Investing.Com
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $.06 $.41
Diluted EPS $.06 $.41
Revenue $ $ 46.01M $ 80.54M
Gross Profit $ $ 35.45M $ 51.45M
Net Income / Loss $ $ 2.97M $ 20.32M
Operating Income / Loss $ $ 3.98M $ 22.08M
Cost of Revenue $ $ 10.56M $ 29.1M
Net Cash Flow $ $ -6.19M $ .11M
PE Ratio